On the subject of good/bad bacteria Recce have been looking at this. It would apply only for oral applications so this CMAX trial may not address this? The quote below can be found here:
https://www.pharmasalmanac.com/articles/applying-a-synthetic-approach-to-the-development-of-a-new-generation-of-antibiotics
RECCE® 327 can also be administered via inhalation. Recce is exploring nebulizer use with the antibiotic for the treatment of patients with tuberculosis. There are additional early indications that the new antibiotic can be used to treat infections of the gastrointestinal tract. Unlike traditional antibiotics, which kill both the bad bacteria in the upper intestine and good bacteria in the lower intestine, RECCE® 327 appears to lose its antibacterial activity by the time it reaches the lower intestine. Preclinical studies also suggest that RECCE® 327 has prophylaxis potential and could possibly be used as a preventive treatment.
On the subject of good/bad bacteria Recce have been looking at...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |